This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (36)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Its Use in Leukemia, Lymphoma and Solid Tumors

ROBERT L. WALL, M.D.; CAPT. FRED G. CONRAD, MC

Arch Intern Med. 1961;108(3):456-482.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since 1946 when mechlorethamine hydrochloride (nitrogen mustard), an alkylating agent, was first reported to exert a suppressive effect on rapidly dividing cells,¹ many new alkylating agents have been synthesized. A few have weathered clinical trial and have proven their effectiveness in the control of chronic leukemias and lymphomas and palliation of patients with malignant tumors. These include triethylene melamine (T.E.M.), triethylene thiophosphoramide (thio-TEPA) and chlorambucil (Leukeran). Recently Arnold, Bourseaux, and Brock² reported the development of a new alkylating agent, cyclophosphamide^* (N,N-bis (β-chloroethyl)-N, O-propylene phosphoric acid ester diamide monohydrate) which promised certain advantages over existing alkylating agents. Clinical trials conducted by Gross and Lambers^3,4 in Germany showed the beneficial effects in 9 of 23 patients with malignant lymphoma.

Cyclophosphamide (Cytoxan^*) was made available in this country for clinical trial in 1959. An early report by Coggins, Ravdin, and Eisman⁶ suggested its continued appraisal in . . . [Full Text PDF of this Article]

Author Affiliations
USAF

From the Department of Medicine, Ohio State University.

Footnotes
Submitted for publication May 19, 1960.

Supported in part by a grant from the United States Public Health Service (C-2472-Hematology).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?